Apyx Medical Inc (APYX) FinancialsAPYXApyx Medical Inc

Apyx Medical Inc (APYX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical Aesthetics, accounting for 85.9% of total sales, equivalent to $10.73M. Another important revenue stream is OEM. Understanding this composition is critical for investors evaluating how APYX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Apyx Medical Inc maintains a gross margin of 63.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13.01%, while the net margin is -22.13%. These profitability ratios, combined with a Return on Equity (ROE) of -96.38%, provide a clear picture of how effectively APYX converts its operational activities into shareholder value.

In the context of the broader market, APYX competes directly with industry leaders such as VANI and QTRX. With a market capitalization of $128.48M, it holds a significant position in the sector. When comparing efficiency, APYX's gross margin of 63.89% stands against VANI's N/A and QTRX's 38.52%. Such benchmarking helps identify whether Apyx Medical Inc is trading at a premium or discount relative to its financial performance.

Apyx Medical has shown strong revenue growth, with Q1 2026 revenue of $12.5 million, a 33% increase from the previous year. The gross margin is stable at around 63% for 2026, indicating good profitability potential despite current losses.